PROTOCOL,PUB_ID,RX_CODE,RX_LABEL,AGE,SEX,RACE,HISPANIC,DISC_FL,DISC_RSN,DISC_RSN_O,EARLY_TERM_FL,TERM_RSN,TERM_AE,NUM_VAC_RECD
127,127-001,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-002,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",26,Female,White,No,Yes,Participant refused study product administration,,Yes,Withdrawal by participant,No,3
127,127-003,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",48,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-004,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Female,Asian,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-005,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",22,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-006,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",19,Female,Asian,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-007,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-008,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",22,Female,White,No,No,,,Yes,Unable to contact participant,No,5
127,127-009,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Female,Asian,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-010,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",19,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-011,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",27,Female,Black/African American,No,Yes,Other,unable to locate participant for follow up,Yes,Unable to contact participant,No,1
127,127-012,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",30,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-013,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",31,Male,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-014,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",18,Female,White,No,No,,,Yes,Participant unable to adhere to visit schedule,No,5
127,127-015,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",32,Male,White,No,No,,,Yes,"Participant relocated, no follow-up planned",No,5
127,127-016,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",43,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-017,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Male,Other,Yes,No,,,No,Scheduled exit visit/end of study,No,5
127,127-018,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",22,Male,White,No,Yes,"Clinical event other than solicited adverse event, HIV infection, or death",,Yes,"Participant relocated, no follow-up planned",No,1
127,127-019,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",27,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-020,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-021,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-022,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Female,Multiracial,No,Yes,Other,Participant moved away to an area without participating study site.,Yes,"Participant relocated, no follow-up planned",No,3
127,127-023,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",18,Female,White,No,Yes,Other,Unable to get in contact,Yes,Unable to contact participant,No,1
127,127-024,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",37,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-025,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",35,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-026,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",47,Male,Black/African American,No,Yes,Investigator reason,,Yes,Unable to contact participant,No,2
127,127-027,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",35,Female,Black/African American,Yes,No,,,No,Scheduled exit visit/end of study,No,5
127,127-028,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",30,Female,White,No,Yes,Other,participant moved out of state permanently and will not be able to attend future study visits,Yes,"Participant relocated, no follow-up planned",No,3
127,127-029,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Female,White,No,No,,,Yes,Unable to contact participant,No,5
127,127-030,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",34,Male,White,Yes,No,,,No,Scheduled exit visit/end of study,No,5
127,127-031,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",50,Male,White,No,Yes,Other,Participant relocated to job further away.,Yes,"Participant relocated, no follow-up planned",No,1
127,127-032,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",24,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-033,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",39,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-034,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",22,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-035,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",26,Male,Asian,No,Yes,Other,Unable to contact participant,Yes,Unable to contact participant,No,1
127,127-036,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",22,Male,Multiracial,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-037,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",24,Female,White,No,Yes,Other,Participant lost to follow-up,Yes,Unable to contact participant,No,2
127,127-038,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",24,Male,Asian,No,No,,,Yes,Withdrawal by participant,No,5
127,127-039,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",27,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-040,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",26,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-041,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",45,Female,Other,No,No,,,Yes,Unable to contact participant,No,5
127,127-042,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",35,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-043,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-044,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",24,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-045,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",20,Female,Black/African American,No,No,,,Yes,"Participant relocated, no follow-up planned",No,5
127,127-046,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",41,Female,Black/African American,No,No,,,Yes,Unable to contact participant,No,5
127,127-047,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",25,Female,White,No,No,,,Yes,Withdrawal by participant,No,5
127,127-048,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",33,Female,Other,Yes,No,,,No,Scheduled exit visit/end of study,No,5
127,127-049,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",19,Female,White,Yes,No,,,No,Scheduled exit visit/end of study,No,5
127,127-050,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",27,Female,Other,Yes,No,,,No,Scheduled exit visit/end of study,No,4
127,127-051,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",30,Female,White,No,Yes,Participant refused study product administration,,No,Scheduled exit visit/end of study,No,2
127,127-052,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",22,Female,White,No,No,,,Yes,Participant unable to adhere to visit schedule,No,5
127,127-053,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",40,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-054,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",20,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-055,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",20,Female,Multiracial,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-056,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",18,Male,White,Yes,No,,,No,Scheduled exit visit/end of study,No,5
127,127-057,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Male,White,Yes,No,,,Yes,Unable to contact participant,No,4
127,127-058,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",33,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-059,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",50,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-060,P6,"0.9% Sodium Chloride at wks(0,16,32,48,64)",35,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-061,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",27,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-062,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",27,Male,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-063,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",47,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-064,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",21,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-065,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",30,Male,Asian,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-066,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",20,Female,Other,Yes,No,,,No,Scheduled exit visit/end of study,No,4
127,127-067,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",28,Male,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-068,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",46,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-069,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-070,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",32,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-071,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-072,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",47,Female,Multiracial,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-073,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",21,Female,White,No,Yes,Other,Participant unable to adhere to visit schedule,Yes,Participant unable to adhere to visit schedule,No,1
127,127-074,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",35,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-075,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",22,Female,Other,No,Yes,Other,"Participant relocated, no follow-up planned",Yes,"Participant relocated, no follow-up planned",No,3
127,127-076,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",37,Male,White,No,Yes,Other,Participant unable to adhere to study visits,Yes,Participant unable to adhere to visit schedule,No,4
127,127-077,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Female,Multiracial,No,No,,,No,Scheduled exit visit/end of study,No,4
127,127-078,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-079,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",24,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-080,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,2
127,127-081,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-082,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",21,Male,White,No,Yes,Solicited adverse event symptom,,No,Scheduled exit visit/end of study,No,2
127,127-083,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",30,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-084,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",33,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-085,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",24,Male,Multiracial,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-086,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",25,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-087,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",28,Female,White,No,Yes,Other,Unable to contact participant,Yes,Unable to contact participant,No,2
127,127-088,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",19,Male,Multiracial,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-089,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",37,Male,Black/African American,No,No,,,Yes,Unable to contact participant,No,4
127,127-090,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",32,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-091,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",39,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-092,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",25,Female,White,No,Yes,Other,Participant is moving and will no longer be able to come to visits.,Yes,Participant unable to adhere to visit schedule,No,3
127,127-093,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Male,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-094,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",31,Male,Black/African American,No,No,,,Yes,Unable to contact participant,No,5
127,127-095,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",50,Male,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-096,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",35,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-097,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",44,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-098,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",49,Female,White,Yes,No,,,No,Scheduled exit visit/end of study,No,5
127,127-099,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",28,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-100,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",32,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-101,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",20,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-102,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",41,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-103,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",25,Female,Multiracial,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-104,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Male,Multiracial,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-105,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",35,Male,Other,Yes,No,,,No,Scheduled exit visit/end of study,No,5
127,127-106,P6,"0.9% Sodium Chloride at wks(0,16,32,48,64)",31,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-107,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",31,Male,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-108,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",23,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-109,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",24,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-110,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",19,Male,Multiracial,No,Yes,Participant refused study product administration,,Yes,Withdrawal by participant,No,2
127,127-111,P6,"0.9% Sodium Chloride at wks(0,16,32,48,64)",24,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-112,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",20,Female,Multiracial,No,Yes,Other,Unable to contact participant- termination,Yes,Unable to contact participant,No,3
127,127-113,T2,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",35,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-114,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",21,Female,Black/African American,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-115,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",47,Female,White,No,Yes,Participant refused study product administration,,Yes,Withdrawal by participant,No,4
127,127-116,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",25,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-117,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",26,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-118,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",29,Female,Other,Yes,Yes,Other,Unable to contact ppt.,Yes,Unable to contact participant,No,3
127,127-119,T5,"5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",21,Male,White,No,No,,,Yes,Unable to contact participant,No,4
127,127-120,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",22,Female,Black/African American,No,No,,,Yes,Withdrawal by participant,No,4
127,127-121,T3,"20 mg/kg VRC07-523LS at wks(0,16,32,48,64)",33,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-122,T4,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",36,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-123,T6,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",43,Male,White,No,No,,,No,Scheduled exit visit/end of study,No,5
127,127-124,T1,"2.5 mg/kg VRC07-523LS at wks(0,16,32,48,64)",25,Female,White,No,No,,,No,Scheduled exit visit/end of study,No,5